Home » Stocks » SLS

SELLAS Life Sciences Group, Inc. (SLS)

Stock Price: $5.80 USD -0.14 (-2.36%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
After-hours: $5.79 -0.01 (-0.17%) Jan 20, 7:17 PM
Market Cap 82.04M
Revenue (ttm) n/a
Net Income (ttm) -20.54M
Shares Out 8.42M
EPS (ttm) -3.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $5.80
Previous Close $5.94
Change ($) -0.14
Change (%) -2.36%
Day's Open 5.95
Day's Range 5.64 - 6.05
Day's Volume 778,640
52-Week Range 1.53 - 17.66

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 days ago

-  Phase 3 REGAL Study of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Patients Underway in United States and Europe  -

GuruFocus - 3 weeks ago

Breast cancer is the second leading cause of death of women in the U.S. alone. Given the prevalence of the disease, it's no surprise that numerous pharmaceutical and biotech companies are sear...

Other stocks mentioned: GLSI, IMMP
GlobeNewsWire - 4 weeks ago

- Early Data from Study of GPS in Combination with Keytruda® in Patients with Advanced WT1(+) Ovarian Cancer Shows Disease Control Rate of 87.5% at a Median Follow-up of 9.4 Weeks  and 100% Pr...

GlobeNewsWire - 1 month ago

- Proceeds Received from Registered Direct Offering, Warrant Exercises and Upfront Fee from China Out-licensing - 

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 13, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the developme...

Benzinga - 1 month ago

Tv Therapeutics (NASDAQ: VTVT) shares were trading higher on Friday after the company said its Phase 2 Simplici-T1 study of TTP399 achieved the primary objective of a statistically significant...

Other stocks mentioned: SLDB, VTVT
GlobeNewsWire - 1 month ago

– Immune Stimulation Augmented by +1,300% at 6-months Post-NPS Treatment –

InvestorPlace - 1 month ago

SLS stock is surging today as investors grow interest in a cancer vaccine from SELLAS Life Sciences in the wake of a rally in GLSI stock. The post SLS Stock: Why SELLAS Life Sciences Is Surgin...

GlobeNewsWire - 1 month ago

- SELLAS to Potentially R eceive Up To $ 202 Million, Inclusive of $7.5 Million Upfront License Fee and $ 8 Million Near-term Milestone s, plus Tiered Royalties -

GlobeNewsWire - 2 months ago

- Received IM PD A pproval to C ommence E nrollment in France for P ivotal Phase 3 S tudy of G alinpepimut -S in A cute M yeloid L eukemia P atients -

GlobeNewsWire - 4 months ago

NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS ) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the deve...

GlobeNewsWire - 5 months ago

- Strengthened balance sheet in August 2020 with $9.2 million private placement priced at-the-market - - Clinical programs for galinpepimut-S, including phase 3 REGAL study, on track, with m...

GlobeNewsWire - 5 months ago

Proceeds to be used to fund the ongoing Phase 3 Acute Myeloid Leukemia REGAL study Proceeds to be used to fund the ongoing Phase 3 Acute Myeloid Leukemia REGAL study

GlobeNewsWire - 8 months ago

NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the developm...

GlobeNewsWire - 8 months ago

Ongoing Clinical Trials Continue to Progress Ongoing Clinical Trials Continue to Progress

GlobeNewsWire - 8 months ago

NEW YORK, April 28, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the develo...

GlobeNewsWire - 9 months ago

NEW YORK, April 16, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the develo...

GlobeNewsWire - 10 months ago

Preliminary data show 11-fold increase in CD8 cytotoxic T-lymphocytes immune response in patients who received single dose of NPS compared to baseline Preliminary data show 11-fold increase in...

GlobeNewsWire - 10 months ago

NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the develo...

Seeking Alpha - 10 months ago

SELLAS Positive Trial Data, And Other News: The Good, Bad And Ugly Of Biopharma

GlobeNewsWire - 10 months ago

- Final analysis shows statistically significant median overall survival of 21 months in patients who received GPS compared to previously reported 5.4 months in the control arm (p-value < 0.0...

GlobeNewsWire - 11 months ago

Regulatory clarity on registration-enabling Phase 3 study design of NPS in combination with trastuzumab in TNBC patients in the adjuvant setting enhances business development efforts Regulator...

GlobeNewsWire - 11 months ago

NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the develop...

GlobeNewsWire - 11 months ago

- Former Klus Pharma and Actinium Pharmaceuticals Executive Brings Extensive Clinical Development Experience in Hematology-Oncology - - Former Klus Pharma and Actinium Pharmaceuticals Executiv...

GlobeNewsWire - 1 year ago

NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the develop...

GlobeNewsWire - 1 year ago

-- Study Open for Enrollment and Patient Screening Underway -- NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late...

GlobeNewsWire - 1 year ago

- Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on November 8, 2019 - - Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on November 8, 2019 -

About SLS

SELLAS Life Sciences Group, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S that is in Phase 2b clinical trials ... [Read more...]

Industry
Biotechnology
Founded
2012
CEO
Dr. Angelos M. Stergiou M.D., ScD h.c.
Employees
5
Stock Exchange
NASDAQ
Ticker Symbol
SLS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for SLS stock is "Buy." The 12-month stock price forecast is 10.00, which is an increase of 72.41% from the latest price.

Price Target
$10.00
(72.41% upside)
Analyst Consensus: Buy